Fluphenazine came into use in 1959.  The injectable form is on the World Health Organization's List of Essential Medicines , the most effective and safe medicines needed in a health system .  It is available as a generic medication .  In the United States the tablets costs between and USD per day for a typical dose.  The wholesale cost in the developing world of the long acting form is between and USD per injection as of 2014.  It was discontinued in Australia around mid 2017. 
Three studies in total compared high doses (100 to 200 mg) of flupenthixol decanoate with the standard doses (~40mg) per injection. Two trials found relapse at medium term (n = 18, 1 RCT , RR , CI to , low quality evidence ) to be similar between the groups. However people receiving a high dose had slightly more favourable medium term mental state results on the Brief Psychiatric Rating Scale (BPRS) (n = 18, 1 RCT , MD -, CI - to -, low quality evidence ). There was also no significant difference in the use of anticholinergic medications to deal with side effects at short term (2 RCTs n = 47, RR , CI to very low quality evidence ). One trial comparing a very low dose of flupenthixol decanoate (~6 mg) with a low dose (~9 mg) per injection reported no difference in relapse rates (n = 59, 1 RCT , RR , CI to , low quality evidence ).